Koyfin Home > Directory > Health Care > Aimmune Therap > EBIT

Aimmune Therap EBIT Chart (AIMT)

Aimmune Therap annual/quarterly EBIT from 2014 to 2020. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Aimmune Therap EBIT for the quarter ending June 06, 2020 was $-66m a 2.10% decrease of -1m year over year
  • Aimmune Therap EBIT for the last 12 months ending June 06, 2020 was $-283m a 14.71% decrease of -42m year over year
  • Aimmune Therap Annual EBIT for 2019 was $-250m a 13.80% decrease of -34m from 2018
  • Aimmune Therap Annual EBIT for 2018 was $-215m a 38.11% decrease of -82m from 2017
  • Aimmune Therap Annual EBIT for 2017 was $-133m a 38.83% decrease of -52m from 2016
Other Income Statement Metrics:
  • Aimmune Therap EBITDA for the quarter ending December 12, 2018 was $-58m a 14.28% decrease of -8m year over year
  • Aimmune Therap Net Income for the quarter ending December 12, 2018 was $-57m a 13.15% decrease of -7m year over year
View Chart On Koyfin

Quarterly AIMT EBIT Data

06/2020$-66m
03/2020$-85m
12/2019$-67m
09/2019$-65m
06/2019$-63m
03/2019$-55m
12/2018$-58m
09/2018$-53m
06/2018$-54m
03/2018$-50m

Annual AIMT EBIT Data

2019$-250m
2018$-215m
2017$-133m
2016$-82m
2015$-36m
2014$-11m
2013$-5m